← Eichor
Condition: Chronic Inflammatory Demyelinating Neuropathy Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Chronic Inflammatory Demyelinating Neuropathy

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg)
Phase 3 · 129 location(s) · Sanofi · NCT06290141Two Dose Levels of Privigen in Pediatric CIDP
Phase 4 · 9 location(s) · CSL Behring · NCT03684018Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Phase 2/Phase 3 · 118 location(s) · Janssen Research & Development, LLC · NCT05327114Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy
Phase 3 · 1 location(s) · Amsterdam University Medical Center (UMC), Location Academic · NCT06714838Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC)
Phase 4 · 4 location(s) · University of Aarhus · NCT04589299A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (
Phase 3 · 131 location(s) · Sanofi · NCT06290128Real-world Study of Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP
Phase N/A · 1 location(s) · Sanofi · NCT06968975Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study
Phase N/A · 1 location(s) · Rigshospitalet, Denmark · NCT06040567A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy
Phase 3 · 180 location(s) · Dianthus Therapeutics · NCT06858579A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflam
Phase 3 · 3 location(s) · Kedrion S.p.A. · NCT06752356Exploratory Study on Predicting CIDP Patients' Decline During IV Immunoglobulin Treatment Adaptation Feasibility.
Phase N/A · 1 location(s) · Centre Hospitalier Universitaire de Liege · NCT06183645A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
Phase 1 · 6 location(s) · Kite, A Gilead Company · NCT07304154IVIG vs SCIG in CIDP
Phase 1 · 1 location(s) · Rutgers, The State University of New Jersey · NCT05584631Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Phase N/A · 1 location(s) · University of Ulm · NCT07154524Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Phase N/A · 2 location(s) · Sanford Health · NCT01793168Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Media
Phase 1 · 1 location(s) · Tongji Hospital · NCT07526493Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart Devices
Phase N/A · 2 location(s) · Heinrich-Heine University, Duesseldorf · NCT07273903A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
Phase 3 · 71 location(s) · argenx · NCT07091630Studying Nerve Function and Structure in Charcot-Marie-Tooth Disease, Anti-MAG Neuropathy and CIDP
Phase N/A · 1 location(s) · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · NCT07461896A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod Dur
Phase N/A · 4 location(s) · argenx · NCT06299748A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
Phase 1 · 8 location(s) · TG Therapeutics, Inc. · NCT06680037Hizentra® in Inflammatory Neuropathies - pHeNIx Study
Phase N/A · 27 location(s) · CSL Behring · NCT04672733CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
EARLY_Phase 1 · 1 location(s) · Tongji Hospital · NCT07337785High-Tech Rehabilitation Pathway for Chronic Adult Neuromuscular Diseases - Fit4MedRob-Chronic MND Project
NA · 7 location(s) · Istituti Clinici Scientifici Maugeri SpA · NCT06881979Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Phase 2 · 1 location(s) · University of Ulm · NCT04881682Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Phase 2 · 138 location(s) · Immunovant Sciences GmbH · NCT07032662Our Study Aims to Determine if Nerve Alterations in Acute GBS and CIDP Detectable by Ultrasound Match Electrodiagnostic
Phase N/A · 1 location(s) · Assiut University · NCT06615622A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
Phase 3 · 82 location(s) · argenx · NCT06920004Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
NA · 1 location(s) · University of Missouri-Columbia · NCT07478172Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating
Phase 3 · 6 location(s) · Octapharma · NCT04929236
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.